Bioanalytical testing

Table 6.9. Typical Method Attributes for LC/MS/MS Methods for Bioanalytical Testing...

All main aspects of analytical and bioanalytical sciences is covered by the conference program. AC CA-05 consists of 12 invited lectures and seven symposia General Aspects of Analytical Chemistry, Analytical Methods, Objects of the Analysis,. Sensors and Tests, Separation and Pre-concentration, Pharmaceutical and Biomedical Analysis, History and Methodology of Analytical Chemistry. Conference program includes two special symposia Memorial one, dedicated to Anatoly Babko and Analytical Russian-Germany-Ukrainian symposium (ARGUS-9). 

In a bioanalytical method, analyses of blank samples (plasma, urine, or other matrix) should be obtained from at least six sources. Each blank sample should be tested for the possible interference of endogenous substances, metabolites, or degradation products. The response of the peaks interfering at the retention time of the analyte should be less than 20% of the response of a lower quantitation limit standard, and should be less than 5% of the response of the internal standard that was used [18, 19]. For dissolution studies, the dissolution media or excipients should not give a peak or spot that has an identical Rt or Rf value with the analyte [20]. 

The ISO protocol for the biochemical response EROD (ISO 23893-2/AWI) as a recent example of a bioanalytical (biomarker) [49,50] method standardised under ISO for fish needs harmonisation with the other test systems and between the laboratories (users) before implementation. Use of biomarkers (biochemical responses) in multi-arrays for environmental monitoring according to Hansen et al. [50] is complementary to chemical analysis since they can alert for the presence of ecotoxic compounds. Bringing into the WFD, the effect-related approaches concerning bioassays and biomarkers are only relevant in the context of the QN of environmental relevant substances and the good chemical status. But it is rather difficult to transfer the monitored biochemical responses or biomarkers into an operational effect-related standard. They serve as the basis for environmental protection against hazardous substances. In relation to... 

It is therefore essential that before pivotal (repeat dose) preclinical studies are initiated, bioanalytical assay development must be completed. This has to cover potential test species, normal and diseased humans. The assays must be validated in the sampling matrix of the toxicity test species, and one should also develop suitable assays for antibodies to the test article. 

New biomarkers will be useful in hepatotoxicity risk assessment if the data quality and validity can be established. The FDA defines a valid biomarker as one that can be measured in an analytical test system with well-established performance characteristics and has an established scientific framework or body of evidence that elucidates the significance of the test results [160]. Although there is no formerly agreed upon path, biomarker validation should include appropriate end-points for study (i.e., toxicology, histopathology, bioanalytical chemistry, etc.) and dose- and time-dependent measurements. An assessment of species, sex and strain susceptibility is also important to evaluate across species differences. More specific considerations for validation of gene and protein expression technologies are reviewed by Corvi et al. and Rifai et al. [144, 147]. 

The first field of application for SdFFF were latex beads, which were used either to test the channels or to produce separation results alternative to other separation techniques. PS nanoparticles used as model surfaces for bioanalytical work have been analyzed by SdFFF [39]. The appealing feature of SdFFF is its ability to characterize particle adlayers—by direct determination of the mass increase performed by observing the differences in retention between the bare and coated particles—with high precision and few error sources the mass of the coating is determined advantageously on a per particle basis. 

Compliance with the FDA guidance can be considered a minimum requirement to test the performance of a bioanalytical method. Due to the fact that the validation process should simulate closely sample analysis, the real and decisive final test for a validated method will always be the sample analysis itself. It is possible that even if it passes all the validation criteria, a bioanalytical method may not be reliable for the analysis of actual samples. This undesirable situation could happen when actual samples (in vivo samples) contain new interferences not present in the spiked samples (in vitro samples) due to a metabolic process and/or other biotransformations. For this reason, bioanalytical laboratories could decide to use more stringent criteria and procedures and/or use actual sample during the method development to further guarantee the validity of the validated methods. 

As analytical and bioanalytical methods must be validated before using them for routine sample analysis and after changing method parameters (see Chapter 8), instruments such as liquid chromatography coupled with mass spectrometry (LC-MS) or tandem mass spectrometry (LC-MS/MS), which are utilized to perform the analysis, should be calibrated and qualified. In addition, an instrument s performance should be tested for suitability prior to use on practically a day-to-day basis. 

C. Rivasseau, P. Racaud, A. Deguin and M.-C. Henion, Development of a bioanalytical phosphatase inhibition test for the monitoring of microcystins in environmental samples, Anal. Chim. Acta, 394 (1999) 243-257. 

---